Treats acne vulgaris. ANDA 202564, held by Actavis Mid Atlantic. Clindamycin Phosphate; Tretinoin.
As of Nov 21, 2026, ANDA 202564 (Clindamycin Phosphate and Tretinoin), held by Actavis Mid Atlantic, was first approved by FDA on Jun 12, 2015, with 0 approved supplements and 0 published complete response letters.
Clindamycin phosphate and tretinoin gel 1.2% / 0.025% is indicated for the topical treatment of acne vulgaris in patients 12 years or older.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 12, 2015 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Clindamycin Phosphate and Tretinoin1.2%;0.025% · gel;topical | Clindamycin Phosphate; Tretinoin | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters